GSK takes bids in European consumer-drug sale

GlaxoSmithKline ($GSK) is steaming ahead with its sale of consumer-drug brands. After unloading U.S. rights to a basket of products last year, the company accepted bids for European rights from private equity players and rival drugmakers. The sale could bring in £500 million, sources said. Report